About Us

Nebulabio is a world-class biotechnology service provider specializing in camelid-derived single-domain antibody (VHH/Nanobody) production, with particular expertise in Alpaca VHH Antibody Production Services. Our dedicated team combines deep knowledge in alpaca immunology, advanced molecular biology, and scalable protein expression to deliver premium-quality, functional VHH antibodies for therapeutic development, diagnostic applications, and advanced research. As pioneers in the field of camelid antibody technology, we have established optimized protocols specifically for alpacas (Vicugna pacos), leveraging their docile nature and robust immune response to produce antibodies with exceptional stability and unique binding properties. We serve pharmaceutical innovators, diagnostic companies, and academic laboratories globally, providing an end-to-end solution from ethical immunization and clone discovery to milligram-scale production and comprehensive characterization.

☞Principle of Alpaca VHH Antibody Production

Our service is grounded in the remarkable biology of alpacas and other camelids, which naturally produce a unique class of antibodies alongside conventional ones. Approximately 50% of their functional antibodies are heavy-chain-only antibodies (HCAbs). These HCAbs lack light chains and the first constant domain (CH1), with antigen-binding function residing entirely in a single variable domain—the VHH, or Nanobody.

When an alpaca is immunized with a target antigen, its adaptive immune system mounts a specific response, generating both conventional antibodies and these heavy-chain-only antibodies. The VHH domains offer distinct advantages that form the foundation of our production service:

• Compact Size & Stability: At ~15 kDa, VHHs are among the smallest known antigen-binding fragments. They exhibit exceptional thermal stability, resistance to extreme pH, and denaturants due to their robust single-domain architecture.

• Unique Paratope Architecture: Alpaca VHHs often feature long, flexible complementarity-determining region 3 (CDR3) loops. This allows them to penetrate and bind cryptic, concave epitopes—such as enzyme active sites or G-protein-coupled receptor (GPCR) pockets—that are inaccessible to conventional antibodies.

• High Solubility & Microbial Expression: Unlike some antibody fragments that aggregate, VHHs are highly soluble and express efficiently in cost-effective microbial systems like E. coli and yeast, facilitating scalable production.

• Low Immunogenicity Potential: While derived from alpacas, VHHs share high sequence homology with human VH domain family III, simplifying humanization for therapeutic applications and reducing immunogenicity risk.

Our service transforms this biological principle into a controlled, reproducible pipeline: managing the alpaca immunization to elicit a potent VHH response, isolating and selecting the best binders, and executing recombinant production to deliver research or development-ready material.

☞Alpaca VHH Antibody Production Process

Our production process is a meticulously controlled, multi-phase operation ensuring the highest standards of quality, specificity, and yield.

 Phase 1: Immunization Program & Immune Monitoring 

• Antigen Design & Preparation: We advise on antigen design (recombinant protein, peptide conjugate, cell immunogen) and formulate it with adjuvants optimized to stimulate a broad, high-titer VHH response in alpacas.

• Ethical Immunization Protocol: Conducted at our AAALAC-accredited animal facility. A multi-dose immunization schedule over 6-8 weeks ensures the development of a mature, affinity-matured immune response.

• Serological Analysis: Regular serum samples are taken to monitor the development of antigen-specific antibodies using ELISA or other relevant assays, guiding the timing for the final lymphocyte harvest.

 Phase 2: Immune Library Construction & Binder Selection 

• Lymphocyte Harvest: At the peak of the immune response, a large volume of blood is collected, and peripheral blood lymphocytes (PBLs) are isolated with high viability.

• VHH Gene Amplification & Library Construction: Total RNA is extracted, and VHH genes are specifically amplified via RT-PCR using primers designed for the unique splicing signal of alpaca HCAb mRNA. The amplified repertoire is cloned into a phage display vector to create an immune VHH library.

• Selection of Specific Binders: The library is screened against the client's target using 3-4 rounds of phage display biopanning. This enriches for and isolates individual VHH clones with the desired affinity and specificity. Positive clones are sequenced and analyzed.

 Phase 3: Recombinant Expression & Process Development 

• Lead Clone Selection & Vector Engineering: The selected VHH sequence(s) are codon-optimized for high-yield expression in the chosen host system (e.g., E. coli BL21 for cytoplasmic or periplasmic expression). The gene is cloned into an expression vector, typically incorporating an N- or C-terminal tag (e.g., His₆-tag, FLAG) for purification and detection.

• Expression Optimization: Small-scale cultures are used to systematically optimize key parameters: inducer concentration (e.g., IPTG), induction temperature, induction time, and media composition to maximize soluble VHH yield.

• Purification Process Development: A scalable purification strategy is established. This typically involves cell lysis (for cytoplasmic expression) or osmotic shock (for periplasmic), followed by capture via Immobilized Metal Affinity Chromatography (IMAC) and polishing using Size-Exclusion Chromatography (SEC) to achieve high purity and remove aggregates.

 Phase 4: Scale-Up Production & Rigorous Quality Control 

• Fed-Batch Fermentation: The optimized process is scaled to multi-liter bioreactors. We monitor and control critical parameters like pH, dissolved oxygen, and nutrient feed to maximize biomass and VHH production.

• Large-Scale Purification: The downstream purification process (IMAC, SEC) is executed at scale to produce milligram to gram quantities of VHH.

• Comprehensive QC & Release Testing: Every batch undergoes stringent analytical testing:

  Purity: >95% by SDS-PAGE and analytical SEC-HPLC.

  Identity: Confirmed by mass spectrometry (LC-MS).

  Binding Activity & Potency: Validated by ELISA and bio-layer interferometry (BLI) or surface plasmon resonance (SPR) to confirm target binding and measure affinity (KD).

  Biophysical Characterization: Thermal stability (Tm) assessed by differential scanning fluorimetry (DSF).

  Safety: Endotoxin levels measured (LAL test) and sterility testing conducted.

• Formulation, Fill & Delivery: The purified VHH is concentrated, dialyzed into the client-specified formulation buffer (e.g., PBS, Tris-HCl), sterile-filtered (0.22 µm), aliquoted, and shipped under appropriate conditions (e.g., lyophilized or on dry ice).

Figure1.Antigen-combining sites of the camelid heavy-chain antibody variable domain (VHH) are constructed by three complementarity-determining regions (CDR1, CDR2 and CDR3)

☞Our Service Workflow

Our client-centered workflow ensures transparency, collaboration, and successful project execution from start to finish.

 Step 1: Project Consultation & Proposal 

We discuss your target, project goals (therapeutic, diagnostic, research), required VHH specifications (affinity, quantity, purity, formulation), and timeline. A detailed project plan and quote are provided.

 Step 2: Antigen Transfer & Immunization Initiation 

Upon project approval and antigen delivery, we commence the ethical alpaca immunization protocol. You receive scheduled updates on immunization progress and serum titer results.

 Step 3: Discovery & Clone Identification Report 

Post-lymphocyte harvest, we construct the immune library, perform panning, and identify lead VHH clones. We deliver a discovery report containing sequences, preliminary binding data, and recommendations for production-scale clones.

 Step 4: Clone Selection & Production Kick-off 

You review the data and select the VHH clone(s) for scale-up production. We finalize the production scale (e.g., 10mg, 50mg, 100mg+), timelines, and deliverables.

Step 5: Process Execution & Production Updates 

Our production team executes the fermentation, purification, and QC. We provide regular progress updates on yield and key milestones.

 Step 6: Final Product Delivery & Support 

Upon successful QC release, we ship the final product along with a comprehensive Certificate of Analysis (CoA). We offer post-delivery technical support for assay integration.

 Our Service Process Flowchart: 

☞Applications of Alpaca VHH Antibodies

VHH antibodies produced from alpacas are versatile tools enabling breakthroughs across multiple sectors:

■ Therapeutic Candidate Development:

• Targeting "Undruggable" Sites: Ideal for inhibiting challenging targets like protein-protein interaction interfaces, ion channels, and allosteric sites on kinases or GPCRs.

• Multispecific Therapeutics: Their simple, single-gene structure makes them perfect building blocks for creating bi-specific or tri-specific molecules.

• CNS-Targeting Drugs: Their small size facilitates engineering for enhanced blood-brain barrier penetration.

■ Diagnostics & Medical Imaging:

• Point-of-Care & In Vitro Diagnostics (IVD): Exceptional stability ensures long shelf-life and reliability in lateral flow assays, ELISA, and biosensors, even in non-refrigerated environments.

• In Vivo Imaging: Rapid tissue penetration and blood clearance enable high-contrast imaging for oncology (tumor detection), cardiology, and inflammation monitoring using PET, SPECT, or optical imaging.

■ Advanced Research Tools:

• Superior Immunoassays: Provide high specificity and low background in demanding applications like super-resolution microscopy, chromatin immunoprecipitation (ChIP), and flow cytometry.

• Intracellular Antibodies (Intrabodies): Can be expressed inside living cells to modulate, degrade, or visualize endogenous proteins, enabling functional genomics and drug discovery research.

• Structural Biology & Epitope Mapping: Their stability and small size facilitate protein complex crystallization and detailed epitope mapping via X-ray crystallography or cryo-EM.

■ Affinity Purification & Bioprocessing: Serve as robust, high-specificity capture ligands for the purification of complex biotherapeutics or difficult-to-express proteins.

Partner with our experts to leverage the unique advantages of the alpaca immune system. Nebulabo’s integrated production service provides a reliable, high-quality path from your antigen to purified, functional Alpaca VHH antibodies, ready to empower your next discovery or development milestone.